In 2008, thrombopoietin receptor agonists (TPO-RAs) were approved in the U.S., and they have significantly improved the treatment of ITP in adults and are now a second-line therapy [6]. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.